Results

eNauka >  Results >  Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Title: Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Authors: Cohen, Jeffrey A; Coles, Alasdair J; Arnold, Douglas L; Confavreux, Christian; Fox, Edward J; Hartung, Hans-Peter; Havrdova, Eva; Selmaj, Krzysztof W; Weiner, Howard L; Fisher, Elizabeth;
Brinar, Vesna V; Giovannoni, Gavin; Stojanovic, Miroslav; Ertik, Bella I; Lake, Stephen L; Margolin, David H; Panzara, Michael A; Compston, D Alastair S;
Issue Date: 2012
Publication: The Lancet
ISSN: 0140-6736 Lancet Search Idenfier
Type: Article
Collation: vol. 380 br. 9856 str. 1819-1828
DOI: 10.1016/s0140-6736(12)61769-3
WoS-ID: 000311435000027
Scopus-ID: 2-s2.0-84869492471
URI: https://enauka.gov.rs/handle/123456789/307860
Metadata source: Migrirano iz RIS podataka
M-category: 
21a+M21a+

1,079
SCOPUSTM
829
OpenCitations
956
WEB OF SCIENCETM
Altmetric
Dimensions
Unpaywall

Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.